Kyowa Kirin was represented by Goldman Sachs Japan Co., Ltd. as financial advisor and Morrison & Foerster LLP. as legal advisor. Orchard Therapeutics was represented by...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Novo Holdings on the deal. Novo Holdings acted as a lead investor in Roslin Tech’s £11 million Series A funding round. Other participating...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Ducentis BioTherapeutics on the deal. Ducentis BioTherapeutics announced its acquisition by Arcutis Biotherapeutics for up to $400 million. Ducentis BioTherapeutics, a portfolio company of...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Flusso on the deal. Flow sensing company Flusso announced their joint sale to a company and a global private equity fund focused on investing...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Insempra on the deal. Insempra announced its strategic investment into Solena Materials Ltd (“Solena”) a synthetic biology company. Solena, a spin-out from Imperial College...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised Jeito Capital on the deal. Jeito Capital, a rapidly emerging independent Private Equity firm dedicated to biotech and biopharma, announced that it has led...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised Vaccitech on the deal, while Davis Polk advised the representatives of the several underwriters. Vaccitech (Nasdaq: VACC) announced its initial public offering...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised Dotmatics, while Willkie Farr & Gallagher LLP advised Insightful Science on the deal. Insightful Science, a leading software provider serving the global...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised Vaccitech on the deal. Vaccitech announced the completion of its $168 million Series B, including the conversion of $43 million in convertible loan...
You must be a Standard 1 Year member to access this content.
